SPAEN is delighted to provide a comprehensive report of the ASCO 2013 medical highlights in GIST and Sarcomas from Dr Axel Le Cesne, Gustave Roussy Institute, Villejuif (France). Sarcomas and GIST were presented at 5 plenary and parallel sessions. These were rich in terms of innovation and therapeutic concepts, reporting study results that may have an impact on our daily practice, whether in GIST or sarcomas.
The GIST Group Switzerland is the patient support group for GIST patients in Switzerland. The association collaborates with healthcare professionals, the pharmaceutical research industry and other patient organizations around the world to achieve the best possible for patients affected with GIST. This year’s GIST Meeting on April 19, 2013 was a special event since the meeting also commemorated the 10th anniversary of the GIST Group Switzerland.
ARIAD Pharmaceuticals just announced the initiation of the Phase II trial of Ponatinib (brand name = Iclusig®) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumours (GIST). The trial is designed to provide initial clinical data evaluating the efficacy and safety of Ponatinib in patients with GIST following failure of prior tyrosine kinase inhibitor (TKI) therapy.
The application “My GIST Companion” is designed to help drive adherence in GIST patients and is now available on iTunes (for iPhone and iPAD). The myGIST Companion app is an interactive digital tool for GIST patients and has been designed with feedback from GIST patient advocates from European Countries. The application allows patients to quickly record their treatment, disease progression, adverse events, and adherence to their therapy.
At 25th of Feb. 2013 the U.S. Food and Drug Administration expanded the approved use of Bayer Pharmaceutical's drug Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease. Stivarga was approved in September 2012 to treat colorectal cancer.
The British Sarcoma Group annual conference in 2013 is being programmed by members of the East Midlands Sarcoma Specialist MDT chaired by Mr Rob Ashford. The Conference starts with a patient advocacy day supported by the three main charities, Sarcoma UK, the Bone Cancer Research Trust and GIST Support UK. Nurses and other clinicians are invited to join the patients from lunch-time for a number of focussed workshops addressing key issues of the day selected by both the charities and the BSG. Read more
EMA will review a marketing authorization application for Masitinib in the treatment of Imatinib resistant GIST
The pharmaceutical company AB Science SA announced on the 4th of October 2012 that the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for Masitinib in the treatment of patients with Imatinib-(Glivec®)-resistant GIST.
The multi-tyrosine kinase inhibitor regorafenib significantly delays disease progression in virtually all subgroups of patients with gastrointestinal stromal tumor (GIST) in the second-line setting, and may even confer benefits when continued after progression, according to subgroup and post-progression analyses of the phase III GRID trial presented at the ESMO 2012 Congress. The current exploratory analyses were presented at ESMO 2012 by Peter Reichardt, MD, PhD, of HELIOS Klinikum in Bad Saarow, Germany. Read more at OncLive. At OncLive there are also related articles and videos on different aspects of GIST treatment available.
The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine. The updated 2012 ESMO Clinical Practice Guidelines for GIST, soft tissue sarcomas and bone sarcomas are now available at the ESMO website.
- Treatment of metastatic and/or unresectable GIST: Bayer has submitted a “New Drug Application (NDA)” to the FDA for Regorafenib.
- European Commission grants marketing authorisation for Pazopanib (Votrient®) in the treatment of certain advanced soft tissue sarcoma subtypes
- ASCO 2012 Report: Medical highlights in GIST and Sarcomas
- Cancerworld article: Recent trials in osteosarcoma and their implications for future studies